FRIDAY, Aug. 8, 2025 (HealthDay News) — A new weight loss pill made by Eli Lilly helped people lose a significant amount of ...

Lilly's second-quarter results reported Thursday were still more than fine: $15.5 billion in revenue beat Wall Street ...

During a 72-week study, those taking the highest dose of orforglipron lost an average of 27.3 pounds. While injections might cause people to lose more weight, a pill has advantages over them, ...

Eli Lilly’s orforglipron cut body weight to a lesser extent than rival Novo Nordisk’s semaglutide, falling into analysts’ ...

Eli Lilly said it plans to submit the pill to the Food and Drug Administration for approval as a weight loss medication this ...

Eli Lilly stock falls 14% after new obesity drug underwhelms in clinical trial. Analysts maintain Buy rating, citing strong ...

This episode of Pharma Pulse covers Bayer’s $2.3 billion cost-cutting overhaul, promising Phase III results for Eli Lilly’s oral GLP-1 therapy orforglipron, and a pivotal court decision clearing the ...

Novo Nordisk shares jumped more than 5% on Friday, extending Thursday’s rally, after Eli Lilly’s obesity pill data fell short of market expectations.

Investing.com - Copenhagen-listed shares of Novo Nordisk (CSE:NOVOb) rose by more than 5% on Friday, extending gains notched in the prior session, after a weight-loss pill from chief rival Eli Lilly ...

A trial of 3,127 patients who took a daily pill for 72 weeks saw an average weight loss per person of 12.3kg. While injectable obesity drugs are peptides designed to replicate the appetite-controlling ...

A new daily weight loss pill could be available soon – and a recent trial has shown that people taking the drug can shed ...

A study showed the drug, which it has licensed to Eli Lilly & Co., resulted in lower weight loss and higher rates of nausea ...